119th Congress (2025-2026)
HR 9661
To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Introduced
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Sponsors
Official sponsors from legislative records.
Primary sponsor
Nicholas A. Langworthy
HouseNYRepublicanDistrict 23
Cosponsor
Kim Schrier
HouseWADemocratDistrict 8
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yours